Imatinib plasma levels: Correlation with clinical benefit in GIST patients

British Journal of Cancer

Volumn 102, Issue 7, 2010, Pages 1198-1199

  Widmer, N ^a   Decosterd, L A ^a   Csajka, C ^a   Montemurro, M ^a   Haouala, A ^a   Leyvraz, S ^a   Buclin, T ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

CANCER PATIENT; DRUG CONCENTRATION; DRUG DOSE COMPARISON; DRUG EXPOSURE; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENOTYPE; HUMAN; LETTER; LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; WILD TYPE;

ALBUMINS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL STROMAL TUMORS; GENOTYPE; GLYCOPROTEINS; HUMANS; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 77950369782     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605584     Document Type: Letter

References (10)

1. Blasdel C, Egorin MJ, Lagattuta TF, Druker BJ, Deininger MW (2007) Therapeutic drug monitoring in CML patients on imatinib. Blood 110(5): 1699-1701; author reply 1701
2. Delbaldo C, Chatelut E, Re M, Deroussent A, Seronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY, Vassal G (2006) Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 12(20): 6073-6078
3. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27(19): 3141-3147
4. Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N, Decosterd LA (2009) Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectro-metry. J Chromatogr B Analyt Technol Biomed Life Sci 877(22): 1982-1996
5. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23): 4342-4349
6. Judson I, Peiming M, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55(4): 379-386
7. Larson RA, Druker BJ, Guilhot FA, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8): 4022-4028
8. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8): 3496-3499
9. Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T (2006) Population pharmacokinetics of imatinib and role of alpha-1-acid glycoprotein. Br J Clin Pharmacol 62(1): 97-112 (Pubitemid 44195246) (Pubitemid 44195246)
10. Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T (2008) Relationship of imatinib free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 98(10): 1633-1640